Post Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors
Abstract Purpose: Accurate HER2 status assessment is crucial to identify patients with HER2-expressing tumors. In this post hoc analysis of DESTINY-PanTumor02 (NCT04482309), we report concordance…
Read the full article10d agoen
You might also wanna read
Returning to PARP Inhibition: Rechallenge with Bevacizumab in Ovarian Cancer
aacrjournals.org·10d ago
Targeted Radiation, Unintended Evolution
aacrjournals.org·10d ago
Molecular and Immune Landscape of Recurrent and/or Distant Metastatic Squamous Cell Carcinoma of the Head and Neck: An EORTC/IMMUCAN Project
aacrjournals.org·10d ago
NT-I7, a Long-Acting Interleukin 7, Increases Lymphocyte Counts and Induces CD8+ T-cell Clonotype Expansion in Patients with Newly Diagnosed High-Grade Gliomas
aacrjournals.org·10d ago
Preoperative Chemoimmunotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab for Previously Irradiated Recurrent HNSCC: A Prospective Phase II Trial
aacrjournals.org·10d ago
The Pan-Tumor Landscape of Gene Amplifications and Copy Number Amplification Ratio for Established and Emerging Clinical Targets
aacrjournals.org·10d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.